Wan et al. further introduced a nongenetic method by conjugating the nucleolin‐binding aptamer AS1411 to PEGylated cholesterol and incorporating it into EVs via mechanical extrusion.[179] These aptamer‐grafted EVs enabled rapid and selective uptake into nucleolin‐positive breast cancer cells, and their aptamer‐mediated delivery of paclitaxel yielded greater antitumor efficacy than free drug or untargeted EV controls. Here, NUCLEOLIN is linked to breast carcinoma.